» Articles » PMID: 22658526

Temporal Trends in General and Age-specific Fertility Rates Among Women with Schizophrenia (1996-2009): a Population-based Study in Ontario, Canada

Overview
Journal Schizophr Res
Specialty Psychiatry
Date 2012 Jun 5
PMID 22658526
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: There is substantial evidence that women with schizophrenia in many parts of the world have fewer children than their peers. Our objective was to analyze recent trends in general and age-specific fertility rates among women with schizophrenia in Ontario, Canada.

Methods: We conducted a repeated cross-sectional population-based study from 1996 to 2009 using population-based linked administrative databases for the entire province of Ontario. Women aged 15-49 years were classified into schizophrenia and non-schizophrenia groups in each successive 12-month period. Annual general and age-specific fertility rates were derived.

Results: The general fertility rate (GFR) among women with schizophrenia was 1.16 times higher in 2007-2009 than in 1996-1998 (95% confidence interval [CI] 1.04-1.31). The annual GFR ratio of women with vs. without schizophrenia was 0.41 (95% CI 0.36-0.47) in 2009, which was slightly higher than the same ratio in 1996 of 0.30 (95% CI 0.25-0.35). Annual age-specific fertility rates (ASFR) increased over time among women with schizophrenia aged 20-24, 25-29, 35-39 and 40-44 years, but the increase was not always statistically significant. Among women aged 20-24 years, the ASFR ratio in women with vs. without schizophrenia was not significant by the end of the study period (0.93, 95% CI 0.70-1.22).

Conclusions: The general fertility rate among women with schizophrenia appears to have increased modestly over the past 13 years. Clinical care and health policy should consider new strategies that focus on the mental health of women with schizophrenia as new mothers, while optimizing healthy pregnancies and child rearing.

Citing Articles

Changes in the pharmacokinetics of lurasidone in a pregnant woman with schizophrenia.

Kawai M, Aratake R, Ogawa T PCN Rep. 2024; 3(4):e70043.

PMID: 39659990 PMC: 11628732. DOI: 10.1002/pcn5.70043.


Adverse obstetric and neonatal outcomes associated with maternal schizophrenia-spectrum disorders and prenatal antipsychotic use: a meta-analysis of 37,214,330 pregnancy deliveries and propensity-score weighted population-based cohort study....

Chan J, Lee K, Correll C, So Y, Chan C, Wong C Mol Psychiatry. 2024; 30(3):954-967.

PMID: 39223277 DOI: 10.1038/s41380-024-02723-1.


COVID-19 second wave: District level study of concentration of confirmed cases and fatality in India.

Ghosh D, Sarkar A, Chouhan D Environ Chall (Amst). 2024; 5:100221.

PMID: 38620919 PMC: 8305220. DOI: 10.1016/j.envc.2021.100221.


Video-based e-learning program for schoolteachers to support children of parents with mental illness: a cluster randomized trial.

Kageyama M, Matsushita A, Kobayashi A, Sakamoto T, Endo Y, Sakae S BMC Public Health. 2023; 23(1):523.

PMID: 36934230 PMC: 10024023. DOI: 10.1186/s12889-023-15426-z.


Risk of interpersonal violence during and after pregnancy among people with schizophrenia: a population-based cohort study.

Leslie K, Barker L, Brown H, Chen S, Dennis C, Ray J CMAJ. 2023; 195(9):E322-E329.

PMID: 36878538 PMC: 9987232. DOI: 10.1503/cmaj.220689.